Aim: To describe a two-stage system of medication product review prior to dispensing or distribution, to decrease risk of error resulting from product changes. Methods: Initial development of a safety strategy occurred during the 2010 state-wide tender of pharmaceutical products. Samples of new medication products were obtained and risk assessed by consensus. Detailed criteria were subsequently developed for: (i) centralised state-based review; and (ii) hospital pharmacy review in-between tenders. Results were fed back to improve evaluation during state-wide tender. Results: In 2010, 14 of 300 (4.6%) new brands of tendered products were assessed as having some risk. Shelf tags or alerts were produced for low or moderate risk products (n = 11, 3.6%). For three products (1.0%), alternative brands were purchased. Subsequently, detailed criteria were developed for both state tender and routine hospital pharmacy product review. In 2014 the hospital's medication safety pharmacists reviewed 242 products in between tender periods. Fifty-two (21.4%) were assessed as having some risk. For seven products (2.8%) an alternative brand was sought. The state tender group now includes a medication safety review during each tender process. Conclusion: Evaluation of new brands during pharmaceutical tender highlighted the importance of having a system to decrease the risk of selection error. The two stages of the medication safety product review strategy are described. First, the centralised review at tender; second, the hospital pharmacy review at procurement and in between tenders, which has further decreased risks associated with new brands and new products.
Background Informing patients about their adverse drug reactions (ADRs) and involving them in their medication management should decrease repeat ADRs. An innovative model for informing patients about their ADRs has been in place at an Australian health network. The health network's ADR Review Committee reviews the ADR reports, assigns causality and makes recommendations. Patients are sent a letter about their ADR along with an alert card. Aim To evaluate the existing ADR model. Method Over a 6‐month period, patients who had an ADR report reviewed by the ADR Review Committee were contacted by telephone within 4 weeks of the review and asked questions about the ADR information sent to them. Patients' discharge summaries were concurrently reviewed for ADR information. Feedback about the model was also sought from the hospital's consumer groups. Results Of the 89 ADR reports reviewed, 76 patients were eligible, and 55 (72%) patients consented to participate in the survey. 50 (91%) patients recalled the name of the causative drug, 53 (96%) recalled the reaction, 48 (87%) recalled the ADR Review Committee's recommendation, 28 (50%) had an alert card in their wallet, and 29 (52%) had shown or were intending to show the letter to their doctor, but only 3 to their pharmacist. 95% of respondents would recommend this model to other hospitals. 35 (63%) patients wanted the letter sent directly to their doctor. Of the 54 discharge summaries reviewed, the ADR was documented in 43 (80%), details of the reaction in 43 (80%) and specific management advice in 10 (19%). Feedback from the hospital's consumer groups (n = 15) was positive and informed improvements to the model. Conclusion The ADR model was well received by patients, who retained the information sent. Patient feedback was used to improve the format and content of the ADR information sent. This model could be adapted by other acute and ambulatory settings to facilitate communication between health professionals and patients to avoid repeat ADRs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.